Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer

Eun Jin Yoo, Jun Chul Park, Eun Hye Kim, Chan Hyuk Park, Choong Nam Shim, Hyun Jik Lee, Hyun Soo Chung, Hyuk Lee, Sung Kwan Shin, SangKil Lee, Chang Geol Lee, Yongchan Lee

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: We performed a retrospective analysis of Asian patients with locally advanced oesophageal cancer to test the hypothesis that an elevated neutrophil-to-lymphocyte ratio is associated with a poor survival rate after definitive concurrent chemoradiotherapy. Methods: In total, 138 patients diagnosed with locally advanced oesophageal cancer (TNM classification of malignant tumours stage II or III) who were treated with definitive concurrent chemoradiotherapy between January 2005 and December 2010 were retrospectively analysed. Definitive concurrent chemoradiotherapy was performed using two different chemotherapy regimens. Results: The median follow-up duration was 39.5 months (range 1.1-93.4). The median progression-free survival was 14.0 months, and the median overall survival was 19.9 months. Compared with the low (<2.0) neutrophil-to-lymphocyte ratio group (n=43, 31.2%), the high (≥2.0) neutrophil-to-lymphocyte ratio group (n=95, 68.8%) exhibited significant decreases in the durations of both progression-free survival and overall survival. Using multivariate analysis, an elevated neutrophil-to-lymphocyte ratio was also significantly associated with decreased progression-free survival (HR 1.799; 95% CI, 1.050-3.083; P=0.032) and overall survival duration (HR 2.115; 95% CI, 1.193-3.749; P=0.010). Conclusions: The pretreatment neutrophil-to-lymphocyte ratio is a useful prognostic marker in patients with locally advanced oesophageal cancer treated with definitive concurrent chemoradiotherapy.

Original languageEnglish
Pages (from-to)846-853
Number of pages8
JournalDigestive and Liver Disease
Volume46
Issue number9
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Chemoradiotherapy
Esophageal Neoplasms
Neutrophils
Lymphocytes
Disease-Free Survival
Survival
Neoplasm Staging
Multivariate Analysis
Survival Rate
Drug Therapy
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Yoo, Eun Jin ; Park, Jun Chul ; Kim, Eun Hye ; Park, Chan Hyuk ; Shim, Choong Nam ; Lee, Hyun Jik ; Chung, Hyun Soo ; Lee, Hyuk ; Shin, Sung Kwan ; Lee, SangKil ; Lee, Chang Geol ; Lee, Yongchan. / Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer. In: Digestive and Liver Disease. 2014 ; Vol. 46, No. 9. pp. 846-853.
@article{c5ad3c9207334a48a40a71e2870471e6,
title = "Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer",
abstract = "Background: We performed a retrospective analysis of Asian patients with locally advanced oesophageal cancer to test the hypothesis that an elevated neutrophil-to-lymphocyte ratio is associated with a poor survival rate after definitive concurrent chemoradiotherapy. Methods: In total, 138 patients diagnosed with locally advanced oesophageal cancer (TNM classification of malignant tumours stage II or III) who were treated with definitive concurrent chemoradiotherapy between January 2005 and December 2010 were retrospectively analysed. Definitive concurrent chemoradiotherapy was performed using two different chemotherapy regimens. Results: The median follow-up duration was 39.5 months (range 1.1-93.4). The median progression-free survival was 14.0 months, and the median overall survival was 19.9 months. Compared with the low (<2.0) neutrophil-to-lymphocyte ratio group (n=43, 31.2{\%}), the high (≥2.0) neutrophil-to-lymphocyte ratio group (n=95, 68.8{\%}) exhibited significant decreases in the durations of both progression-free survival and overall survival. Using multivariate analysis, an elevated neutrophil-to-lymphocyte ratio was also significantly associated with decreased progression-free survival (HR 1.799; 95{\%} CI, 1.050-3.083; P=0.032) and overall survival duration (HR 2.115; 95{\%} CI, 1.193-3.749; P=0.010). Conclusions: The pretreatment neutrophil-to-lymphocyte ratio is a useful prognostic marker in patients with locally advanced oesophageal cancer treated with definitive concurrent chemoradiotherapy.",
author = "Yoo, {Eun Jin} and Park, {Jun Chul} and Kim, {Eun Hye} and Park, {Chan Hyuk} and Shim, {Choong Nam} and Lee, {Hyun Jik} and Chung, {Hyun Soo} and Hyuk Lee and Shin, {Sung Kwan} and SangKil Lee and Lee, {Chang Geol} and Yongchan Lee",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.dld.2014.05.009",
language = "English",
volume = "46",
pages = "846--853",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier",
number = "9",

}

Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer. / Yoo, Eun Jin; Park, Jun Chul; Kim, Eun Hye; Park, Chan Hyuk; Shim, Choong Nam; Lee, Hyun Jik; Chung, Hyun Soo; Lee, Hyuk; Shin, Sung Kwan; Lee, SangKil; Lee, Chang Geol; Lee, Yongchan.

In: Digestive and Liver Disease, Vol. 46, No. 9, 01.01.2014, p. 846-853.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer

AU - Yoo, Eun Jin

AU - Park, Jun Chul

AU - Kim, Eun Hye

AU - Park, Chan Hyuk

AU - Shim, Choong Nam

AU - Lee, Hyun Jik

AU - Chung, Hyun Soo

AU - Lee, Hyuk

AU - Shin, Sung Kwan

AU - Lee, SangKil

AU - Lee, Chang Geol

AU - Lee, Yongchan

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: We performed a retrospective analysis of Asian patients with locally advanced oesophageal cancer to test the hypothesis that an elevated neutrophil-to-lymphocyte ratio is associated with a poor survival rate after definitive concurrent chemoradiotherapy. Methods: In total, 138 patients diagnosed with locally advanced oesophageal cancer (TNM classification of malignant tumours stage II or III) who were treated with definitive concurrent chemoradiotherapy between January 2005 and December 2010 were retrospectively analysed. Definitive concurrent chemoradiotherapy was performed using two different chemotherapy regimens. Results: The median follow-up duration was 39.5 months (range 1.1-93.4). The median progression-free survival was 14.0 months, and the median overall survival was 19.9 months. Compared with the low (<2.0) neutrophil-to-lymphocyte ratio group (n=43, 31.2%), the high (≥2.0) neutrophil-to-lymphocyte ratio group (n=95, 68.8%) exhibited significant decreases in the durations of both progression-free survival and overall survival. Using multivariate analysis, an elevated neutrophil-to-lymphocyte ratio was also significantly associated with decreased progression-free survival (HR 1.799; 95% CI, 1.050-3.083; P=0.032) and overall survival duration (HR 2.115; 95% CI, 1.193-3.749; P=0.010). Conclusions: The pretreatment neutrophil-to-lymphocyte ratio is a useful prognostic marker in patients with locally advanced oesophageal cancer treated with definitive concurrent chemoradiotherapy.

AB - Background: We performed a retrospective analysis of Asian patients with locally advanced oesophageal cancer to test the hypothesis that an elevated neutrophil-to-lymphocyte ratio is associated with a poor survival rate after definitive concurrent chemoradiotherapy. Methods: In total, 138 patients diagnosed with locally advanced oesophageal cancer (TNM classification of malignant tumours stage II or III) who were treated with definitive concurrent chemoradiotherapy between January 2005 and December 2010 were retrospectively analysed. Definitive concurrent chemoradiotherapy was performed using two different chemotherapy regimens. Results: The median follow-up duration was 39.5 months (range 1.1-93.4). The median progression-free survival was 14.0 months, and the median overall survival was 19.9 months. Compared with the low (<2.0) neutrophil-to-lymphocyte ratio group (n=43, 31.2%), the high (≥2.0) neutrophil-to-lymphocyte ratio group (n=95, 68.8%) exhibited significant decreases in the durations of both progression-free survival and overall survival. Using multivariate analysis, an elevated neutrophil-to-lymphocyte ratio was also significantly associated with decreased progression-free survival (HR 1.799; 95% CI, 1.050-3.083; P=0.032) and overall survival duration (HR 2.115; 95% CI, 1.193-3.749; P=0.010). Conclusions: The pretreatment neutrophil-to-lymphocyte ratio is a useful prognostic marker in patients with locally advanced oesophageal cancer treated with definitive concurrent chemoradiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84906306748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906306748&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2014.05.009

DO - 10.1016/j.dld.2014.05.009

M3 - Article

C2 - 24970014

AN - SCOPUS:84906306748

VL - 46

SP - 846

EP - 853

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 9

ER -